title: Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation.
abstract: The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry's perceived tarnished image. Pharma has responded by embarking on a range of initiatives. Other sectors, including NIH, have also responded. Academic drug discovery groups have appeared to support the transition of innovative academic discoveries and ideas into attractive drug discovery opportunities. Part 1 of this two-part series discussed the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summarized the supporting data for and against these criticisms. This second installment will focus on the current challenges facing the pharmaceutical industry and Pharma's responses, focusing on the industry's changing perspective and new business models for coping with the loss of talent and declining clinical pipelines as well as presenting some examples of recent drug discovery successes.
authors.affiliation: Moulder Center for Drug Discovery Research, Temple University School of Pharmacy , 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States.
authors.forename: Magid
authors.initials: M
authors.lastname: Abou-Gharbia
authors.forename: Wayne E
authors.initials: WE
authors.lastname: Childers
mesh_terms: D001702:Biopharmaceutics; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods*; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D016568:Drugs, Generic; D004526:Efficiency; D006801:Humans; D062069:Inventions; D020416:Outsourced Services / Q000191:economics / Q000592:standards; D010330:Patents as Topic; D012106:Research / Q000191:economics; D057170:Translational Research, Biomedical
chemical_list: D016568:Drugs, Generic